CLL

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses.

A combination of Imbruvica and venetoclax showed significantly prolonged progression-free survival in patients with untreated CLL, an expert explained.

I’m very grateful for my SLL medication, but I never thought a side effect of the medication would affect my wardrobe for the rest of my life.

I haven’t been too happy with my blood work with CLL, but I try to enjoy what I can — including apples during fall.

In patients with certain B-cell blood cancers, heart-related side effects may occur less after receiving second-generation BTK inhibitors.

Patients with treatment-naive CLL/SLL experienced long-term improved efficacy when treated with Brukinsa compared with bendamustine plus Rituxan.

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care chemoimmunotherapy in patients with untreated chronic lymphocytic leukemia.

Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than published data, an expert said.

For patients with relapsed or refractory CLL, an expert explained that it’s important to understand the order of how treatments are given.

When I am triggered by something related to the cancer I have, I start going down a negative rabbit hole but remind myself to be vigilant when this happens.

As a patient with chronic lymphocytic leukemia, I recently gleaned three new insights from my oncologist and phlebotomist.

My quality of life has improved a lot after starting on a BTK inhibitor, but some things will never be the same — like being in crowded places without a mask!

Two dear friends have introduced helpful items to me, such as a chemo jacket since I became cold in the treatment room.

A phase 1b trial showed promising results among patients with relapsed or refractory chronic lymphocytic leukemia.

Patients with relapsed or refractory CLL or SLL may benefit from receiving Brukinsa instead of Imbruvica, as Brukinsa demonstrated superior effectiveness.

I’ve recently started on chemotherapy pills instead of infusions and the bitterness reminds me to accept not only the bitterness of the pill, but in life too.

From good news for a rock star to the deaths of stage and screen stars, here’s what’s happening in the cancer space this week.

After recently losing my aunt, I realized that cancer has given me a new perspective on life, which reminds me that every day has meaning.

The discussion will wrap up with perspectives on the future of CLL treatment, including anticipated improvements in patient care and quality of life, emerging therapies, and evolving patient roles in care decisions.

The discussion will explore the impact of fixed-duration treatments on quality of life, benefits and challenges compared with continuous therapy, financial considerations, and lifestyle goals during and after treatment.

Treatment with Brukinsa may lower the rates of switching therapies compared with Calquence and Imbruvica in chronic lymphocytic leukemia.

The discussion will cover fixed-duration treatments vs continuous therapy for CLL and provide a brief overview of venetoclax-based regimens approved for 12 cycles with obinutuzumab and 24 cycles with rituximab.

The discussion will cover experiences with CLL treatment, focusing on key factors in treatment decisions, how care teams educate patients about options, strategies for discussing adverse events, and communicating adverse effects to the care team.

The discussion will cover the current CLL treatment landscape, including first-line and later-line options; the medical experts will review first-line treatments, approach to treatment selection, factors influencing recommendations, and strategies for shared decision-making with patients.